3SBio's (HKG:1530) attributable profit rose 35% to 2.09 billion yuan in 2024 from 1.55 billion yuan in 2023, according to a Tuesday filing with the Hong Kong bourse.
Earnings per share at the biopharmaceutical company increased to 0.85 yuan from 0.62 yuan a year earlier. Analysts at Visible Alpha estimated EPS per share at 0.83 yuan.
Revenue grew 17% to 9.11 billion yuan from 7.82 billion yuan in the previous year. Visible Alpha analysts forecast revenue at 8.90 billion yuan.
The company declared a final dividend of HK$0.25 per share, payable Aug. 15 to shareholders on record as of July 25.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。